Santaris Pharma A/S
Records under this name other than patents Santaris Pharma A/S holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,133,455 | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,653,252 | Short interfering RNA (siRNA) analogues Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,045,518 | Amino-LNA, thio-LNA and alpha-L-oxy-LN Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,790,493 | MICROMIRs Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,450,564 | Micromirs Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,288,356 | MicroRNAs Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,528 | Antisense oligomers targeting PCSK9 Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,906,871 | MicromiRs Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 10,358,643 | Poly Oligomer Compound with Biocleavable Conjugates Formerly held In force · High confidence | In force | High confidence | |
| US 7,785,834 | Soluble TNF receptors and their use in treatment of disease Formerly held In force Term ended Nov 10, 2026 · From the USPTO record | In force | Term ended Nov 10, 2026 | From the USPTO record |